ClinicalTrials.gg
Active, not recruitingNCT06938516HYIMPACTUpdated Nov 20, 2026

Prospective Observational Study On The Impact Of Nebilet In Blood Pressure Control In Hypertensive Patients (HYIMPACT)

An observational study in Hypertension, sponsored by A.Menarini Asia-Pacific Holdings Pte Ltd. Active, not recruiting at 52 sites in 7 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by A.Menarini Asia-Pacific Holdings Pte Ltd (part of Menarini Group) · Observational

How we know

Updated Nov 20, 2026Now Active, not recruitingStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
4,537
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Hypertension with a site in Indonesia — 5 open to participants now, 6 under way, none of them phase 3. Hypertension · Indonesia.

Started
2023
with 3 others
Observational
8 of 22
3 open now
Registered
18th of 22
by date
Lead sponsor
1 of 22
A.Menarini Asia-Pacific Holdings Pte Ltd

Among the 22 studies in Hypertension with a site in Indonesia, this one is one of 4 that started in 2023, is one of 8 observational ones, and was the 18th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 22 studies in Hypertension with a site in Indonesia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Hypertension with a site in Indonesia, or all of them as a file.
02

Study summary

The HYIMPACT study (IMPACT of Nebilet® in Blood Pressure Control in Patients with Hypertension) is a multinational, multicenter, observational, prospective, longitudinal real-world evidence study designed to assess the effectiveness and safety of Nebilet® (nebivolol) in hypertensive patients. The study aims to evaluate changes in systolic and diastolic blood pressure from baseline to 12, 24, and 36 months, as well as treatment adherence, quality of life, prescription patterns, and cardiovascular outcomes.

A total of approximately 5,000 hypertensive patients with or without cardiovascular comorbidities will be enrolled across seven Asian countries (Malaysia, Indonesia, the Philippines, Korea, Vietnam, Thailand, and Taiwan). Patients newly initiated on Nebilet®-based treatment or already receiving Nebilet® for no more than two weeks prior to screening will be eligible for inclusion.

Patients will be followed at regular intervals for up to three years. The study will also assess the correlation between home and office blood pressure measurements and compare Nebilet® monotherapy with combination therapy in achieving target blood pressure control. The findings from this study will provide real-world insights into the clinical management of hypertension with Nebilet® and its impact on patient outcomes.

Read the detailed description

Introduction. Hypertension remains one of the leading risk factors for cardiovascular morbidity and mortality worldwide, contributing significantly to the burden of stroke, heart failure, and other cardiovascular diseases. Despite advancements in antihypertensive therapies, real-world data on long-term blood pressure control, treatment adherence, and patient-reported outcomes remain insufficient, particularly in diverse populations across Asia. While clinical trials have established the efficacy of various antihypertensive agents, the applicability of these findings to routine clinical practice remains unclear. Beta-blockers, particularly nebivolol, a third-generation β1-selective adrenergic antagonist with nitric oxide-mediated vasodilatory properties, have demonstrated favorable hemodynamic effects, improved vascular function, and better tolerability compared to traditional beta-blockers. However, there is a lack of robust real-world evidence assessing its long-term impact on blood pressure control and cardiovascular outcomes.

The HYIMPACT study is a multinational, multicenter, observational, longitudinal study designed to evaluate the real-world effectiveness, safety, and adherence of Nebilet® (nebivolol) in hypertensive patients across seven Asian countries. This study will provide insights into the clinical utility of Nebilet® in achieving sustained blood pressure control over time, while also assessing the influence of cardiovascular risk factors on treatment outcomes. By systematically collecting data from patients in routine clinical settings, HYIMPACT aims to bridge the gap between controlled clinical trials and real-world practice, offering valuable evidence to optimize hypertension management strategies.

Study Objectives. HYIMPACT aims to assess the impact of Nebilet®-based treatment on systolic and diastolic blood pressure control from baseline to 12, 24, and 36 months. The study will determine the proportion of patients achieving target blood pressure levels (\<140/90 mmHg) and evaluate adherence using the Morisky 8-Item Medication Adherence Scale (MMAS). Additionally, the study will compare the effectiveness of Nebilet® monotherapy versus combination therapy in achieving blood pressure control. Patient-reported outcomes will be analyzed using the SF-36 and MINICHAL questionnaires, providing insights into the impact of treatment on quality of life. The study will also assess the correlation between home and office blood pressure measurements and investigate the association between Nebilet® use and major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular mortality.

Study Design and Population. HYIMPACT is an observational, prospective, longitudinal study enrolling approximately 5,000 hypertensive patients across Malaysia, Indonesia, the Philippines, Korea, Vietnam, Thailand, and Taiwan. Eligible patients will be adults aged 18 years or older with newly diagnosed or uncontrolled hypertension, defined as an office systolic blood pressure of at least 140 mmHg and/or diastolic blood pressure of at least 90 mmHg at screening. Patients may be included if they have either been newly prescribed Nebilet® or have been on Nebilet®-based treatment for no more than two weeks prior to enrollment. Individuals with recent major cardiovascular events within the last three months, severe heart failure classified as NYHA Class IV, or contraindications to Nebilet® as per the Summary of Product Characteristics will be excluded. The study will involve 300 to 500 physicians, ensuring representation across a wide range of real-world clinical settings.

Variables to be Collected. The study will systematically collect patient demographic and clinical data, including medical history, cardiovascular risk factors such as diabetes, obesity, and hypercholesterolemia, and medication use. Blood pressure measurements will be recorded at baseline and at each follow-up visit, with additional data collected on prescription patterns, dose adjustments, and patient adherence. Laboratory parameters, including lipid profiles, glycated hemoglobin (HbA1c), and renal function markers, will be documented when available. Cardiovascular outcomes such as MACE, including myocardial infarction, stroke, and cardiovascular mortality, will be monitored throughout the study.

Follow-Up and Data Collection. Patients will be evaluated at baseline and followed up at 12, 24, and 36 months. Blood pressure will be measured at each visit using standardized protocols, and home blood pressure readings will be encouraged to assess their correlation with office measurements. Patient-reported quality of life and adherence assessments will be conducted using validated questionnaires. Any adverse events, including treatment-emergent and serious adverse events, will be documented. Data will be recorded in an electronic case report form (eCRF) using the CLINYTICS platform, ensuring consistency and standardization across study sites.

Quality Control Measures. To ensure high data quality, the study will implement standardized definitions and data collection procedures across all sites. Investigators will receive training on study protocols, and automated validation checks within the eCRF system will help identify inconsistencies. Regular site audits will be conducted to monitor compliance, and periodic investigator meetings will be held to review study progress. Ethics committee approvals will be obtained in each participating country, and all data will be handled in compliance with Good Clinical Practice (GCP) guidelines and local data protection regulations.

Statistical Analysis. Continuous variables such as blood pressure values will be summarized as means with standard deviations, while categorical variables will be presented as frequencies and percentages. Changes in systolic and diastolic blood pressure over time will be analyzed using paired t-tests and repeated measures ANOVA, with non-parametric alternatives applied when normality assumptions are not met. The effectiveness of Nebilet® monotherapy versus combination therapy will be assessed using logistic regression for categorical outcomes and ANOVA for continuous variables. Cox proportional hazards models will evaluate the association between Nebilet® treatment and cardiovascular outcomes. Pearson correlation coefficients will be used to analyze the relationship between home and office blood pressure measurements, and structural equation modelling (SEM) will be applied to address potential regression dilution bias.

Study Governance and Data Ownership. HYIMPACT is an investigator-led study with data collection coordinated through a centralized electronic data management system. Each participating physician retains ownership of individual patient data, while consolidated and anonymized study results will be used for scientific analysis and publication. Patient confidentiality will be strictly maintained through secure data storage, anonymization, and regulatory compliance with local data protection laws.

The findings from HYIMPACT will provide valuable insights into the long-term real-world effectiveness of Nebilet® in managing hypertension. By analyzing treatment adherence, quality of life, and cardiovascular outcomes over time, this study will contribute to optimizing hypertension treatment strategies and improving patient care across diverse healthcare settings.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • High Blood Pressure
  • Nebivolol in high blood pressure
  • Use of Nebilet in high blood pressure
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients from South-East Asia countries will be enrolled.

The names of the participating countries are as follows:

  1. Taiwan
  2. Indonesia
  3. South Korea
  4. Philippines
  5. Thailand
  6. Malaysia
  7. Vietnam

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients ≥ 18 years of age with either newly diagnosed or uncontrolled hypertension (office SBP ≥140 and/or DBP ≥90 mmHg recorded at the time of screening) as per ESC/ESH guidelines 2018.
  • Hypertensive patients - with or without cardiovascular comorbidities (such as coronary artery disease, heart failure, peripheral artery disease, cerebrovascular disease, arrhythmias, and valvular heart disease) - who are newly prescribed or are already on Nebilet based treatment (no more than for 2 weeks at screening).
  • Hypertensive patients willing to provide consent to participate in the study.
  • Women of reproductive age who are willing to use adequate means of .

Exclusion criteria

Exclusion Criteria:

  • Patients with recent cardiovascular event within less than 3 months.
  • Patient with heart failure based on (NYHA) Functional Classification- Class IV.
  • Patients with to Nebilet based treatment as per respective Summary of Product Characteristic (SmPC) which in the treating physician's judgment may jeopardize the subject by his or her participation in this study or may hamper his or her ability to perform and complete procedures required in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
4,537 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Change in mean sitting systolic blood pressure from baseline to one year of treatment in hypertensive patients on Nebilet based treatment.

    Blood pressure of the study patients will be recorded and documented within a time period of every 3 months since baseline visit.

    Time frame: Baseline to 12 months

Secondary outcomes

  1. To assess the impact of Nebilet based treatment in changing diastolic BP (DBP) in hypertensive patients in real-world setting from baseline to one year of treatment.

    Change in mean sitting Diastolic Blood Pressure (DBP) from baseline to one year of treatment in hypertensive patients on Nebilet based combination treatment.

    Time frame: Baseline to 12 months

  2. Change in mean sitting SBP and DBP from baseline to two years and at the end of three years in hypertensive patients on Nebilet based treatment.

    Change in mean sitting SBP and DBP from baseline to 24 months and 36 months of treatment.

    Time frame: Baseline to 24 months and 36 months

  3. To evaluate the proportions of patients achieving target BP goal (<140/90 mm Hg) at different time points (12 months, 24 months, and 36 months of treatment) with Nebilet based as combination treatment.

    For hypertensive patients with coronary artery disease (CAD), the age-wise SBP control goal is ≤130 mmHg in 18-64 years age-group, and 130 -140 mmHg in ≥65 years age group. Whereas the DBP control goal in these patients is 70-79 mmHg for all age groups.

    Time frame: 12, 24 and 36 months

  4. To assess the association of various risk factors (diabetes, obesity, and hypercholesterolemia) on development of major cardiac events in patients who achieve BP control over a period of 36 months.

    The number of Major Adverse Cardiac Events (MACE) such as acute myocardial infarction, acute coronary syndrome, stroke, heart failure, all-cause death and cardiovascular death in patients who achieved target BP control over a period of three years by categorizing the patients as per the risk factors (diabetes, obesity, and hypercholesterolemia).

    Time frame: 36 months

  5. To study the prescription patterns of Nebilet®-based treatment in terms of frequency per day in real-world settings.

    Understanding the prescription patterns of Nebilet in the participating South-East Asia countries.

    Time frame: 36 months

  6. To study the prescription patterns of Nebilet®-based treatment in terms of dose in milligrams in real-world settings.

    Understanding the prescription patterns of Nebilet in the participating South-East Asia countries.

    Time frame: 36 months

  7. To study the prescription patterns or Nebilet®-based treatment in terms of treatment duration in months, in real-world settings.

    Understanding the prescription patterns of Nebilet in the participating South-East Asia countries.

    Time frame: 36 months

  8. To assess the impact of Nebilet®-based treatment on the quality-of-life of patients using MINICHAL questionnaire.

    Understanding the prescription patterns of Nebilet in the participating South-East Asia countries.

    Time frame: Baseline, 12 months, 24 months and 36 months

  9. To assess the patient-reported outcomes using a short form 36 health survey (SF-36 questionnaire) .

    Assessment of patient reported outcome using short from 36 health survey questionnaire.

    Time frame: Baseline, 12 month, 24 month, and 36 month

  10. To assess patient adherence to treatment by an 8-item Morisky Medication Adherence Scale every 3 months after baseline, till 36 months.

    Assessment of patient adherence to treatment.

    Time frame: 3 month, 6 month, 9 month, 12 month, 15 month, 18 month, 21 month, 24 month, 27 month, 30 month, 33 month, 36 month

07

Study locations

52 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Nov 2028, 59 months after the start.

Of 81 industry-sponsored observational studies under Hypertension, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 59 months is above that.

Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2029 → Jun 2029, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2025
First posted
Apr 22, 2025
StartActual
Dec 20, 2023
Primary completionEst.
Nov 2028
CompletionEst.
Jun 2029was Mar 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 20, 2026
Sites
21 sites added, 18 sites removed
Show 21 added (6 Vietnam, 5 Indonesia, 4 Thailand, 3 Malaysia, 2 Taiwan, 1 South Korea)
  • National Cardiovascular Center Harapan Kita Hospital · Jakarta, Indonesia
  • Metropolitan Medical Centre Hospital · Jakarta, Indonesia
  • Bidakara Medical Centre · Selatan, Indonesia
  • Siloam Hospital Surabaya · Surabaya, Indonesia
  • Siloam International Hospital · Banten, Indonesia
  • DrThong,Leow,Chiam & Partners · Kuala Lumpur, Malaysia
  • Klinik Pembangunan Sdn. Bhd · Kuala Lumpur, Malaysia
  • Pantai HKL · Kuala Lumpur, Malaysia
  • Eunpyeong St. Mary's Hospital · Seoul, South Korea
  • Far Eastern Memorial Hospital (FEMH) · New Taipei City, Taiwan
  • Kaohsiung Medical University Hospital (KMUH) · Kaohsiung City, Taiwan
  • Burapha University · Chon Buri, Thailand
  • Anand Mahidhol Hospital · Lopburi, Thailand
  • Central Chet Institute · Nonthaburi, Thailand
  • Chiang Mai University · Chiang Mai, Thailand
  • Nhan Dan Gia Dinh Hospital · Ho Chi Minh City, Vietnam
  • CanTho General Hospital · Can Tho, Vietnam
  • Hanoi Heart Hospital · Hanoi, Vietnam
  • Bach Mai Hospital · Hanoi, Vietnam
  • Cho Ray Hospital · Ho Chi Minh City, Vietnam
  • Hue Central Hospital · Huế, Vietnam
Show 18 removed
  • Bidakara Medical Centre · Selatan, Indonesia
  • National Cardiovascular Center Harapan Kita Hospital · Jakarta, Indonesia
  • Metropolitan Medical Centre Hospital · Jakarta, Indonesia
  • Eunpyeong St. Mary's Hospital · Seoul, Korea, Republic of
  • Mawar Medical Centre · Seremban, Malaysia
  • DrThong,Leow,Chiam & Partners · Kuala Lumpur, Malaysia
  • Klinik Pembangunan Sdn. Bhd · Kuala Lumpur, Malaysia
  • Pantai HKL · Kuala Lumpur, Malaysia
  • Far Eastern Memorial Hospital (FEMH) · New Taipei, Taiwan
  • Kaohsiung Medical University Hospital (KMUH) · Kaohsiung, Taiwan
  • Burapha University · Chon Buri, Thailand
  • Anand Mahidhol Hospital · Lopburi, Thailand
  • Chiang Mai University · Chiang Mai, Thailand
  • Central Chet Institute · Nonthaburi, Thailand
  • CanTho General Hospital · Can Tho, Vietnam
  • Hanoi Heart Hospital · Hanoi, Vietnam
  • Cho Ray Hospital · Ho Chi Minh, Vietnam
  • Hue Central Hospital · Hue, Vietnam
Nov 20, 2026
Study completion
Mar 2029→Jun 2029
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Active, not recruiting
    21 sites added, 18 sites removed
    Show 21 added (6 Vietnam, 5 Indonesia, 4 Thailand, 3 Malaysia, 2 Taiwan, 1 South Korea)
    • National Cardiovascular Center Harapan Kita Hospital · Jakarta, Indonesia
    • Metropolitan Medical Centre Hospital · Jakarta, Indonesia
    • Bidakara Medical Centre · Selatan, Indonesia
    • Siloam Hospital Surabaya · Surabaya, Indonesia
    • Siloam International Hospital · Banten, Indonesia
    • DrThong,Leow,Chiam & Partners · Kuala Lumpur, Malaysia
    • Klinik Pembangunan Sdn. Bhd · Kuala Lumpur, Malaysia
    • Pantai HKL · Kuala Lumpur, Malaysia
    • Eunpyeong St. Mary's Hospital · Seoul, South Korea
    • Far Eastern Memorial Hospital (FEMH) · New Taipei City, Taiwan
    • Kaohsiung Medical University Hospital (KMUH) · Kaohsiung City, Taiwan
    • Burapha University · Chon Buri, Thailand
    • Anand Mahidhol Hospital · Lopburi, Thailand
    • Central Chet Institute · Nonthaburi, Thailand
    • Chiang Mai University · Chiang Mai, Thailand
    • Nhan Dan Gia Dinh Hospital · Ho Chi Minh City, Vietnam
    • CanTho General Hospital · Can Tho, Vietnam
    • Hanoi Heart Hospital · Hanoi, Vietnam
    • Bach Mai Hospital · Hanoi, Vietnam
    • Cho Ray Hospital · Ho Chi Minh City, Vietnam
    • Hue Central Hospital · Huế, Vietnam
    Show 18 removed
    • Bidakara Medical Centre · Selatan, Indonesia
    • National Cardiovascular Center Harapan Kita Hospital · Jakarta, Indonesia
    • Metropolitan Medical Centre Hospital · Jakarta, Indonesia
    • Eunpyeong St. Mary's Hospital · Seoul, Korea, Republic of
    • Mawar Medical Centre · Seremban, Malaysia
    • DrThong,Leow,Chiam & Partners · Kuala Lumpur, Malaysia
    • Klinik Pembangunan Sdn. Bhd · Kuala Lumpur, Malaysia
    • Pantai HKL · Kuala Lumpur, Malaysia
    • Far Eastern Memorial Hospital (FEMH) · New Taipei, Taiwan
    • Kaohsiung Medical University Hospital (KMUH) · Kaohsiung, Taiwan
    • Burapha University · Chon Buri, Thailand
    • Anand Mahidhol Hospital · Lopburi, Thailand
    • Chiang Mai University · Chiang Mai, Thailand
    • Central Chet Institute · Nonthaburi, Thailand
    • CanTho General Hospital · Can Tho, Vietnam
    • Hanoi Heart Hospital · Hanoi, Vietnam
    • Cho Ray Hospital · Ho Chi Minh, Vietnam
    • Hue Central Hospital · Hue, Vietnam
    Study completion Mar 2029→Jun 2029
    + 3 other changes: verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06938516
Responsible party
Sponsor
First posted
Apr 22, 2025
Start date
Dec 20, 2023
Primary completion
Nov 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Dr Radhika Mehta
study director · A. Menarini Asia-Pacific Holding Pte Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion